SWM
BMRN icon

SHP Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

SHP Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$858 Buy
15
+1
+7% +$55 ﹤0.01% 1639
2026
Q1 		$791 Buy
+14
New +$816 ﹤0.01% 1521

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

SHP Wealth Management's BMRN Position: Q2 2026 in Review

SHP Wealth Management increased its BioMarin Pharmaceuticals (BMRN) stake by 7.1% in Q2 2026, buying an estimated $55 and bringing the position to 15 shares worth $858. The position accounts for ﹤0.01% of the portfolio, ranked #1639.

SHP Wealth Management first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • SHP Wealth Management held 15 shares of BioMarin Pharmaceuticals worth $858 as of Q2 2026.
  • SHP Wealth Management bought 1 BioMarin Pharmaceuticals share in Q2 2026, an estimated $55.
  • BioMarin Pharmaceuticals made up ﹤0.01% of SHP Wealth Management's portfolio in Q2 2026, its #1639 holding.
  • SHP Wealth Management first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on SHP Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.